Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.

Cancers·2026

Same author

Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic.

JCO oncology practice·2025

Same author

Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.

The oncologist·2025

Same author

Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm.

JCO oncology practice·2025

Same author

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Search research articles

Related Experiment Video

Updated: May 6, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

PSMA-Directed Theranostics in Prostate Cancer.

Salman Ayub Jajja¹, Nandini Sodhi², Ephraim E Parent³

¹NYMC-Landmark Medical Center, Woonsocket, RI 02895, USA.

|August 28, 2025

Summary

This summary is machine-generated.

Prostate cancer treatments are advancing with prostate cancer-specific membrane antigen (PSMA) targeting. PSMA-based PET imaging and therapeutics offer improved detection and management for advanced prostate cancer.

Keywords:

PSMA theranostics antibody drug conjugates immunotherapy in prostate cancer prostate cancer therapeutics radioligand therapy

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Related Experiment Videos

Last Updated: May 6, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Area of Science:

Oncology
Radiochemistry
Immunotherapy

Background:

Prostate cancer is a leading cause of cancer death in men, with high-risk cases often becoming resistant to standard treatments.
Prostate cancer-specific membrane antigen (PSMA) is overexpressed in prostate cancer and linked to poorer survival.
Current diagnostic methods for staging and treatment selection have limitations.

Purpose of the Study:

To review the emerging field of PSMA-based theranostics for prostate cancer.
To highlight advancements in PSMA-targeted diagnostics and therapeutics.
To discuss the integration of PSMA theranostics into clinical practice.

Main Methods:

Review of recent clinical trials and scientific literature on PSMA-based PET radiopharmaceuticals.
Analysis of PSMA-targeted therapeutic strategies including radioligands, CAR-T, BiTEs, and ADCs.
Discussion of PSMA expression as a biomarker for risk stratification and treatment response.

Main Results:

PSMA-based PET imaging demonstrates superior sensitivity and specificity compared to traditional methods for detecting prostate cancer lesions.
Several PSMA-targeted therapies are under development, showing promise in clinical trials.
Increased PSMA expression is a validated independent risk factor for adverse outcomes in prostate cancer.

Conclusions:

PSMA-based theranostics represent a significant advancement in prostate cancer management.
These approaches are increasingly being integrated into standard care protocols for improved patient outcomes.
Targeting PSMA offers a promising strategy for both diagnosis and treatment of advanced prostate cancer.